MELBOURNE, Australia, Oct. 05, 2020 (GLOBE NEWSWIRE) — Opthea Limited (ASX: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, is pleased to announce that Jeremy Read more » »